Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II PIC regimen study in advanced or relapsed/refractory extranodal NK/T-cell lymphoma
ChiCTR2100047130Phase 2Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Jun 2021
- Modality
- Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaspargase, PD-1 Monoclonal Antibody and tucidinostat in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Beijing Tongren Hospital. Primary endpoint: Complete response rate. Started Jun 2021; status: recruiting.
02
Drugs
pegaspargasePD-1 Monoclonal Antibodytucidinostat
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR2100047130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047130.